Myeloma Paper of the Day, October 5th, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Study of safety and efficacy of Cilta-cel for RR (relapsed refractory) myeloma finds median PFS not reached (12-month estimate 68%); high ferritin, high-risk cytogenetics & EMD associated with inferior PFS; signal for prior BCMA-TT; SPMs in 5.5%.”
Source: Robert Orlowski/X
Authors: Surbhi Sidana, Krina K. Patel, Lauren C Peres, Radhika Bansal, Mehmet Hakan Kocoglu, Leyla Shune, Shebli Atrash, Kinaya Smith, Shonali Midha, Christopher J Ferreri, Binod Dhakal, Danai Dima, Patrick Costello, Charlotte Wagner, Ran Reshef, Hitomi Hosoya, Lekha Mikkilineni, Djordje Atanackovic, Saurabh Chhabra, Ricardo D Parrondo, Omar Nadeem, Hashim Mann, Nilesh Kalariya, Vanna Hovanky, Gabriel DeAvila, Ciara L Freeman, Frederick L Locke, Melissa Alsina, Sandy Wong, Megan M Herr, Myo Htut, Joseph P. McGuirk, Douglas W Sborov, Jack Khouri, Thomas Martin, Murali Janakiram, Yi Lin and Doris K Hansen.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas, MD Anderson Cancer Center including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023